RxDoctor Payments Data

Joyce Burton, DO

Internal Medicine · Delanson, NYNPI 1306803895

Payments from drug & device makers

$3,617in general payments, 2019–2025

Across 87 payments — averaging $41.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$823
  • GSK$796
  • Novo Nordisk$499
  • AbbVie$461
  • Lilly USA, LLC$407
  • Bayer$168
  • plus $462 from 10 others

What the payments were for

  • Food & beverage$3,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,617 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$72,345
Medicare patients
272
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$96,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$92,366
OxycontinOxycodone Hcl35$90,016
OzempicSemaglutide69$77,716
TrulicityDulaglutide60$68,285
FarxigaDapagliflozin Propanediol39$51,145
VraylarCariprazine Hcl31$47,797
JardianceEmpagliflozin36$46,711
MounjaroTirzepatide25$37,269
CreonLipase/Protease/Amylase14$23,946
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,348
XareltoRivaroxaban16$13,795
RybelsusSemaglutide11$13,029
MyrbetriqMirabegron13$9,340
KerendiaFinerenone11$6,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$407$105,55485 claims
GSKTrelegy Ellipta, Breo Ellipta$796$97,406108 claims
PfizerEliquis$133$96,79978 claims
Novo NordiskOzempic, Rybelsus$499$90,74580 claims
AbbVieVraylar, Creon, Synthroid$461$73,40468 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$823$70,73272 claims
Astellas Pharma US IncMyrbetriq$21$9,34013 claims
BayerKerendia$168$6,36811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Delanson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →